Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

KaloBios licenses Humaneering tech to Novartis.
May 2007
SHARING OPTIONS:

PALO ALTO, Calif.—KaloBios Pharmaceuticals Inc. a privately held biopharmaceutical company, announced in April an agreement with Novartis to non-exclusively license KaloBios' proprietary Humaneering technology for use at Novartis' research sites to develop human antibodies for therapeutic indications. This is the first such non-exclusive technology transfer that KaloBios has offered for its Humaneering platform.
 
As part of the transition plan, KaloBios has agreed to "Humaneer" three additional antibodies for Novartis in addition to the three that have been successfully completed as part of a pilot research and development relationship.
 
"KaloBios sees the last two years of diligence culminating in this agreement as a clear validation of the Humaneering technology," says Dr. Mark Alfenito, executive vice president, corporate development for KaloBios. 
 
This license also brings in sufficient new revenue to fund the company's clinical studies for KB001  for Pseudomonas infections and three clinical programs for KB002  for inflammation and autoimmune indications into mid 2008, according to David Pritchard, KaloBios' CEO.
 
Humaneering is KaloBios' proprietary method for converting non-human antibodies into engineered human antibodies for therapeutic drug applications. The system reportedly has the advantage of maintaining epitope specificity and increasing affinity. The "Humaneered" antibodies are said to be as close as, if not closer to, human germline sequences than the products of fully human antibody generation techniques.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.